124 related articles for article (PubMed ID: 11194432)
1. An experience with transvaginal sonography in gynaecologic tumour surveillance.
Carter J
Aust N Z J Obstet Gynaecol; 2000 Nov; 40(4):438-41. PubMed ID: 11194432
[TBL] [Abstract][Full Text] [Related]
2. Transvaginal sonography, color flow imaging, computed tomographic scanning, and CA 125 as a routine follow-up examination in women with pelvic tumor: detection of recurrent disease.
Weiner Z; Beck D; Brandes JM
J Ultrasound Med; 1994 Jan; 13(1):37-41. PubMed ID: 7636952
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer screening.
van Nagell JR; Gallion HH; Pavlik EJ; DePriest PD
Cancer; 1995 Nov; 76(10 Suppl):2086-91. PubMed ID: 8635005
[TBL] [Abstract][Full Text] [Related]
4. The role of cul-de-sac aspiration cytology in the follow-up of ovarian cancer.
Engblom PR; Grènman SE; Klemi PJ; Hirvonen TE; Rantanen VT; Salmi TA
Acta Oncol; 1995; 34(6):783-5. PubMed ID: 7576746
[TBL] [Abstract][Full Text] [Related]
5. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
[TBL] [Abstract][Full Text] [Related]
6. Playing the waiting game ... the asymptomatic patient with recurrent ovarian cancer detected only by rising Ca125 levels.
Fleming LW
Scott Med J; 2001 Jun; 46(3):81-3. PubMed ID: 11501326
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors.
Zanetta G; Rota S; Lissoni A; Meni A; Brancatelli G; Buda A
Gynecol Oncol; 2001 Apr; 81(1):63-6. PubMed ID: 11277651
[TBL] [Abstract][Full Text] [Related]
9. Detecting Asymptomatic Recurrence in Early-Stage Endometrial Cancer: The Value of Vaginal Cytology, Imaging Studies, and CA-125.
Lee JY; Kim JH; Seo JW; Kim HS; Kim JW; Park NH; Song YS
Int J Gynecol Cancer; 2016 Oct; 26(8):1434-9. PubMed ID: 27465903
[TBL] [Abstract][Full Text] [Related]
10. Detecting recurrent ovarian cancer: revisit the values of whole-body CT and serum CA 125 levels.
Wang PH; Huang YT; Ng KK; Chou HH; Lu HY; Ng SH; Lin G
Acta Radiol; 2019 Oct; 60(10):1360-1366. PubMed ID: 30678481
[No Abstract] [Full Text] [Related]
11. Fifth Alon Dembo memorial workshop: case 3.
Schwartz PE
Int J Gynecol Cancer; 2010 Oct; 20(11 Suppl 2):S24-6. PubMed ID: 20975356
[TBL] [Abstract][Full Text] [Related]
12. [Clinical impact of FDG-PET in patients with suspected recurrent ovarian cancer].
Cuenca Cuenca JI; Borrego Dorado I; Vázquez Albertino R; Gómez Camarero P; Sanz Viedma S; Fernández López R
Rev Esp Med Nucl; 2008; 27(6):411-7. PubMed ID: 19094899
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of transvaginal color Doppler sonography, transvaginal sonography and CA 125 for prediction of ovarian malignancy.
Sengoku K; Satoh T; Saitoh S; Abe M; Ishikawa M
Int J Gynaecol Obstet; 1994 Jul; 46(1):39-43. PubMed ID: 7805982
[TBL] [Abstract][Full Text] [Related]
15. [Computer tomography for gynaecological carcinomas (authors's transl)].
Haertel M
Rofo; 1980 Jun; 132(6):652-7. PubMed ID: 6450126
[TBL] [Abstract][Full Text] [Related]
16. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer.
Murakami M; Miyamoto T; Iida T; Tsukada H; Watanabe M; Shida M; Maeda H; Nasu S; Yasuda S; Yasuda M; Ide M
Int J Gynecol Cancer; 2006; 16 Suppl 1():99-107. PubMed ID: 16515575
[TBL] [Abstract][Full Text] [Related]
17. The Diagnostic Value of Transvaginal Sonograph (TVS), Color Doppler, and Serum Tumor Marker CA125, CEA, and AFP in Ovarian Cancer.
Zhang F; Zhang ZL
Cell Biochem Biophys; 2015 Jun; 72(2):353-7. PubMed ID: 25582421
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic value of abdominal computerized tomography. After-care of gynecologic malignancies].
Stummvoll W; Holböck E; Schoissengeier A
Gynakol Geburtshilfliche Rundsch; 1994; 34(1):55-7. PubMed ID: 8019176
[No Abstract] [Full Text] [Related]
19. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
[TBL] [Abstract][Full Text] [Related]
20. Recurrent female pelvic cancer: assessment with transrectal ultrasonography.
Meanwell CA; Rolfe EB; Blackledge G; Docker MF; Lawton FG; Mould JJ
Radiology; 1987 Jan; 162(1 Pt 1):278-81. PubMed ID: 3538149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
